Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2). J of Skin. 2017;1(3.1):s38. doi:10.25251/skin.1.supp.37